BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 14, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 21, 2015
View Archived Issues
JAK2 inhibitor shows promise for the treatment of leukemia
Read More
Factor XIa and KLKB1 inhibitors reported in BMS patent
Read More
Apricus seeks partnering for Femprox in female sexual dysfunction
Read More
BioSyent acquires Canadian rights to Photocure's Cysview
Read More
Biota advances RSV program with start of phase I trial of BTA-585
Read More
LY-3130481: a TARPgamma8-dependent AMPA antagonist for epilepsy
Read More
Odomzo approved in E.U. for locally advanced basal cell carcinoma
Read More
CSIR scientists describe PDE5A inhibitors
Read More
AM-Pharma discloses phosphatase-like proteins
Read More
Bristol-Myers Squibb synthesizes AAK1 inhibitors
Read More
Pan-Pim kinase inhibitors investgated at Amgen for anticancer activity
Read More
Janus Biotherapeutics collaborates with Roche on autoimmune diseases
Read More
ExeGi Pharma announces clinical trial of probiotic Visbiome in HIV infection
Read More
Sprout Pharmaceuticals to be acquired by Valeant
Read More
Cellceutix reports results from phase I trial of Kevetrin in solid tumors
Read More
MAP/MAPKAP-2 inhibitor MK-2684 shows promise for the treatment of asthma
Read More
Isotope Technologies acquires DOTA-zoledronate for radiotherapy and imaging
Read More
EMA to review MAA for palbociclib plus endocrine therapy for HR+/HER2- metastatic breast cancer
Read More
4D Pharma's IBS candidate Blautix enters phase I trial
Read More
MAA validated for emtricitabine/rilpivirine/tenofovir combination tablet
Read More
Janssen starts phase II trial of sirukumab in patients with depression
Read More
Novartis acquires rights to ofatumumab for autoimmune disease from GSK
Read More
Janssen applies for E.U. approval of long-acting paliperidone palmitate
Read More
EMA accepts Takeda's MAA for ixazomib
Read More
